Approval · Notice of Compliance 27334 · 2022
XERMELO: Notice of Compliance 27334
Issued January 5, 2022
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 27334
- Date
- January 5, 2022
- Company
- Ipsen Biopharmaceuticals Canada IncMississauga, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Updates to the Product Monograph. Updates to Package Insert
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| XERMELO | Not yet assigned | — |
Medicinal ingredients
- TELOTRISTAT ETIPRATE 250 MG per TAB